The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C05 | Vasoprotectives | |
| 3 | C05C | Capillary stabilizing agents | |
| 4 | C05CA | Bioflavonoids |
| Code | Title | |
|---|---|---|
| C05CA01 | Rutoside | |
| C05CA02 | Monoxerutin | |
| C05CA03 | Diosmin | |
| C05CA04 | Troxerutin | |
| C05CA05 | Hidrosmin | |
| C05CA51 | Rutoside, combinations | |
| C05CA53 | Diosmin, combinations | |
| C05CA54 | Troxerutin, combinations |
| Active Ingredient | Description | |
|---|---|---|
| Diosmin |
Diosmin (diosmetin 7-O-rutinoside), a flavone derivative also known as venosmine, is a glycoside of diosmetin, which in turn is the 4'-methoxy derivative of luteolin. Diosmin prolongs the vasoconstrictor effect of norepinephrine on the vein wall, increasing venous tone, and therefore reducing venous capacitance, distensibility, and venous stasis. This increases the venous return and reduces venous hyperpressure present in patients suffering from CVI. |
|
| Flavonoids |
|
|
| Hidrosmin |
|
|
| Kaempferol |
|
|
| Rutoside |
|
|
| Troxerutin |
The pharmacodynamic effects of oxerutins have been demonstrated in different in vitro and in vivo studies. At the cellular level the capability of oxerutins to protect the vascular wall from the oxidative attack of activated blood cells and its affinity to the endothelium of capillaries and venoles could be shown. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| DAFLON Film-coated tablet | Marketing Authorisation Holder | MPI, EU: SmPC | |
| EUVEIN 500 Film-coated tablet | Health Sciences Authority (SG) | MPI, Generic | |
| PAROVEN Capsule | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
